# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-SEC
PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patientsConsistent data across subgroups under...
Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consiste...
NeuroSense Therapeutics Ltd, a company developing novel treatments for severe neurodegenerative diseases, today announced it ha...
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neur...
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate ...